Arrhythmias & electrophysiology
Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban: A Cross-Sectional Survey of Atrial Fibrillation Patients
Authors' conclusion
Patients may not disclose their nonadherence to prescribers, and attitudes related to apixaban nonadherence differ among patients with mild nonadherence versus poor adherence.
Study context
- Population
- AF patients reporting apixaban nonadherence, 2 academic health systems41.5% women
- Participants
- 419 patients
- Exposure
- Poor adherence vs mild nonadherence
- Outcome
- Patient-reported reasons for nonadherence and level of nonadherence (validated 3-item adherence measure)
Methodological detailssurvey, 2 academic health systems, multivariable logistic regression
- Survey
- 2 academic health systems
- Multivariable logistic regression
Main finding
As reported in the abstract
Attitudes/beliefs associated with adherence score <80
Poor adherence vs Mild nonadherenceOdds ratio (95% CI)
Not believing apixaban was needed
12.24(2.25–66.47)
Medication cost
3.97(1.67–9.42)
Fear of severe bleeding
3.28(1.20–8.96)
Observational data: associations, not effects.
Further findings
Strategies selected as helping "a great deal/a lot" (adherence score <80)
- Bloodwork to evaluate efficacy
- 56%
- Physician counseling about adherence
- 55%
- Having a reversal agent
- 39%
Nondisclosure of nonadherence to providers
- Almost one-half of all patients did not disclose nonadherence
Original publication
Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban: A Cross-Sectional Survey of Atrial Fibrillation Patients. JACC Adv. Published 27 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →